NCT05793684 - AD816 Crossover Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

November 9, 2023

Study Completion Date

November 9, 2023

Conditions

OSAObstructive Sleep Apnea

Interventions

DRUG

Period A

Week 1: Viloxazine low dose + placebo; Week 2: Viloxazine high dose + placebo

DRUG

Period B

Week 1: AD816 low dose; Week 2: AD816 high dose

DRUG

Period C

Week 1: Placebo + Placebo; Week 2: Placebo + Placebo

Trial Locations (3)

Clayton Sleep Institute, St Louis

Santa Monica Clinical Trials, Los Angeles

Brigham and Women's Hospital, Boston